Denali Therapeutics Inc
denalitherapeutics.comDenali Therapeutics Inc (NASDAQ: DNLI) is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases. The company does not generate product revenue from approved medicines; its income comes from collaboration agreements with partners including large pharmaceutical companies. Denali was founded and is headquartered in South San Francisco, California. Its pipeline targets diseases including Parkinson's disease, ALS, Alzheimer's disease, and lysosomal storage disorders, with a platform centered on its Transport Vehicle technology designed to cross the blood-brain barrier. As a pre-commercial biotechnology company, Denali funds operations primarily through collaboration and license payments rather than product sales.
Products & Services
Clinical-stage drug pipeline targeting neurodegenerative diseases including Parkinson's disease, ALS, Alzheimer's disease, and lysosomal storage disorders. Proprietary Transport Vehicle (TV) platform for blood-brain barrier drug delivery.
Revenue Model
Collaboration and license revenue from pharmaceutical partnership agreements. No approved product revenue as of the 10-K filed 2026-02-26.
Customers & Markets
Pharmaceutical company collaborators. End markets include patients with neurodegenerative diseases.
Geographic Exposure
Headquartered in South San Francisco, California. Geographic revenue mix not determinable from available filing excerpts.
Financial Snapshot
Loading...
